Multiple-gene sequencing rapidly replaced BRCA1- and BRCA2-specific tests for patients with breast cancer, yielding a significantly greater detection of cancer-causing gene mutations without increasing prophylactic mastectomies, study data showed.
“In general, multigene panel tests yield more clinically useful results and are rapidly becoming the norm,” Allison Kurian, MD, associate professor of medicine and health research and policy at Stanford University School of Medicine, said in a press release. “Newly diagnosed women should ask their doctors whether they may be appropriate candidates for genetic testing. They should also advocate for the opportunity to discuss genetic testing and its implications with an experienced clinician, such as a genetic counselor, in a timely manner.”
The researchers used the SEER registries for Georgia and Los Angeles to perform a population-based retrospective cohort study of 5,026 patients (mean age, 59.9 years) diagnosed with breast cancer between 2013 and 2015.
The main outcomes included the type of testing patients received, test results, patient experiences with testing, treatment and receipt of prophylactic mastectomy.
Researchers linked slightly more than one-fourth of patients (n = 1,316; 26.2%) to genetic test results from any laboratory.
During the study period, multiple-gene sequencing overtook BRCA testing in usage. Multiple-gene sequencing comprised 25.6% of tests in 2013 compared with 66.5% in 2015, whereas BRCA-only testing fell from 74.4% in 2013 to 33.5% in 2015.
Genetic counselors ordered multiple-gene sequencing more frequently than BRCA-only testing (25.5% vs. 15.3%).
Multiple-gene sequencing also was more often delayed until after surgery (32.5% vs. 19.9%).
Compared with BRCA testing, multiple-gene sequencing increased detection of any pathogenic gene variant (higher-risk patients, 12% vs. 7.8%; average-risk patients, 4.2% vs. 2.2%).
Multiple-gene testing also detected more variants of uncertain significance than BRCA-only testing, particularly among patients of ethnic or racial minorities (white patients, 23.7% vs. 2.2%; black patients, 44.5% vs. 5.6%; Asian patients, 50.9% vs. 0%).
Researchers observed no association between multiple-gene testing and an increase in the use of prophylactic mastectomy.
Prophylactic mastectomy occurred most often with pathogenic variants in BRCA1 or BRCA2 (BRCA, 79%; other variant; 37.6%; variant of uncertain significance, 30.2%; negative, 35.3%).
“Our findings demonstrated that sequencing more genes offers the potential advantage of more clinically valuable information and also pinpoints gaps that must be bridged to realize that potential,” Kurian and colleagues wrote.
These gaps included optimal targeting for higher-risk patients, the timeliness of testing, and the closing of ethnic and racial disparities in sequencing “less familiar” genetic variants. – by Andy Polhamus
Disclosures: Kurian reports research funding to Stanford University from Myriad Genetics for an unrelated project. The other authors report no relevant financial disclosures.